Category: Myasthenia Gravis

UCB announces positive Phase 3 results for rozanolixizumab in generalised myasthenia gravis

Positive topline results from UCB MycarinG study investigating the efficacy and safety of rozanolixizumab in patients with generalised myasthenia gravis (gMG) Study met primary and all secondary endpoints with statistical significance Rozanolixizumab was well tolerated with no new observed safety signals  UCB plans regulatory submissions for rozanolixizumab in gMG from Q3 2022  December 10th, 2021…